Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26638246 | 1.00 | AR (0.66) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19459671 | 1.00 | AR (0.66) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19460127 | 1.00 | AR (0.66) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19460233 | 1.00 | AR (0.66) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19460183 | 1.00 | AR (0.66) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19459617 | 0.93 | AR (0.58) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19459805 | 0.93 | AR (0.58) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19460174 | 0.93 | AR (0.58) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19459809 | 0.93 | AR (0.58) | ARHTTHIF1ACYP2C9TSHR | |
| SCHEMBL19459745 | 0.93 | AR (0.58) | ARHTTHIF1ACYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-03-27 | — | — | US | disclosed |
| US-11919874-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-05 | — | — | US | disclosed |
| EP-3442942-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2023-11-15 | — | — | EP | disclosed |
| EP-3442942-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-20210387957-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-16 | — | — | US | disclosed |
| US-20210387957-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-16 | — | — | US | disclosed |
| US-11142508-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-10-12 | — | — | US | disclosed |
| US-11142508-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-10-12 | — | — | US | disclosed |
| US-20200317628-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| US-20200317628-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| US-20170298033-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-10-19 | — | — | US | disclosed |
| US-20170298033-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-10-19 | — | — | US | disclosed |
| WO-2017177307-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | AR 1/4885HTT 2896/4885HIF1A 1231/4885 |
| US-20210387957-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | AR 1/4885HTT 2896/4885HIF1A 1231/4885 |
| US-20200317628-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | AR 1/4885HTT 2805/4885HIF1A 1458/4885 |
| US-11919874-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | AR, SHBG, NR5A1 | AR 1/4885HTT 2896/4885HIF1A 1231/4885 |
| US-11142508-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | AR, SHBG, NR5A1 | AR 1/4885HTT 2805/4885HIF1A 1458/4885 |
| US-20170298033-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | AR 1/4885HTT 2896/4885HIF1A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.